Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

• Tác giả: Laleh Amiri-Kordestani, Ting-Yu Chen, Mallorie H Fiero, Xin Gao, Kirsten B Goldberg, Nicole Gormley, Gwynn Ison, Paul G Kluetz, Abhilasha Nair, Marc Neilson, Richard Pazdur, William F Pierce, Tiffany K Ricks, Mirat Shah, Shenghui Tang, Marc R Theoret, Hui Zhang
• Ngôn ngữ: eng
• Ký hiệu phân loại: 621.38152 Electrical, magnetic, optical, communications, computer engineering; electronics, lighting
• Thông tin xuất bản: United States : Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2025
• Bộ sưu tập: NCBI
• ID: 747866

Tóm tắt

From 2014 through 2019, the US Food and Drug Administration (FDA) granted approval to six indications for poly (ADP-ribose) polymerase (PARP) inhibitors in advanced epithelial ovarian cancer (EOC). From 2022 through 2023, these six indications were withdrawn or narrowed after observation of a potential detrimental effect on overall survival (OS) in four randomized controlled trials. The indications for niraparib, olaparib, and rucaparib for the treatment of